- On 28 May 1996 at 12:30:30, Duncan Jodrell (jodrell.aaa.icrf.icnet.uk) sent the message
I apologise for raising an issue which has been discussed extensively in
the not too distant past.
My question is whether there are literature data (or personal experiences)
to support the use of ODA in patients with chemotherapy induced
neutropenic sepsis, where overwhelming gram -ve septicaemia can develop
rapidly in the absence of appropriate antibiotic therapy.
Duncan Jodrell
Senior Lecturer in Medical Oncology
from: Duncan Jodrell
Back to the Top
- On 29 May 1996 at 10:29:14, "Dianne M. Brundage" (brund004.-at-.maroon.tc.umn.edu) sent the message
There wasn't any literature on once daily aminoglycosides in febrile neutropenia
when I recently searched. We've been utilizing it in our chemotherapy-induced
neutropenia patients (both inpatient and outpatient management), but counts
return quickly to normal (we also use filgrastim) so I'm not sure this is a true
test. Our physicians and nurses like it. We have relatively limited experience
in AML patients s/p chemotherapy, however, it appears to be no different from
conventional dosing. Our experience with impaired renal function (ie dosing q48
hours) is also very limited. Usually, we do not use it as monotherapy against
gram negative organisms, and we have very few resistant gram negative organisms.
In message writes:
> PharmPK - Discussions about Pharmacokinetics
> Pharmacodynamics and related topics
>
> pharmpk PK/PD Discussion LISTSERV
>
> I apologise for raising an issue which has been discussed extensively in
> the not too distant past.
>
> My question is whether there are literature data (or personal experiences)
> to support the use of ODA in patients with chemotherapy induced
> neutropenic sepsis, where overwhelming gram -ve septicaemia can develop
> rapidly in the absence of appropriate antibiotic therapy.
>
> Duncan Jodrell
> Senior Lecturer in Medical Oncology
>
> from: Duncan Jodrell
> see WWW Server at: http://www.cpb.uokhsc.edu/pkin/pkin.html for more info
>
> Also see: http://www.cpb.uokhsc.edu/pkin/pkin.html
>
Dianne M. Brundage, Pharm.D., BCPS
Methodist Hospital Pharmacy
6500 Excelsior Blvd
Minneapolis, MN 55426
Back to the Top
- On 29 May 1996 at 10:29:16, Steve Ebert (sebert.aaa.facstaff.wisc.edu) sent the message
The largest published study was authored by the EORTC and published in
Annals of Internal Medicine, around 1992-3 or so. It compared ODA plus
once-daily ceftriaxone with 8-hourly amikacin and ceftazidime. No
differences in efficacy noted. A delay in onset of nephrotoxicity was
observed in ODA group. SCE
Back to the Top
- On 31 May 1996 at 10:59:39, G.Peterson.aaa.pharm.utas.edu.au (Greg Peterson) sent the message
>PharmPK - Discussions about Pharmacokinetics
> Pharmacodynamics and related topics
>
>pharmpk PK/PD Discussion LISTSERV
>
>I apologise for raising an issue which has been discussed extensively in
>the not too distant past.
>
>My question is whether there are literature data (or personal experiences)
>to support the use of ODA in patients with chemotherapy induced
>neutropenic sepsis, where overwhelming gram -ve septicaemia can develop
>rapidly in the absence of appropriate antibiotic therapy.
>
>Duncan Jodrell
>Senior Lecturer in Medical Oncology
Hi Duncan,
The following very recent paper might be of some interest - perhaps you
have seen it already.
Author(s) R Hatala, T Dinh, DJ Cook
Title Once-daily aminoglycoside dosing in immunocompetent adults: A
meta-analysis
Source Annals of Internal Medicine 124: 8 (APR 15 1996)
Page(s) 717
Greg
Gregory Peterson
Senior Lecturer
Tasmanian School of Pharmacy
University of Tasmania GPO Box 252C
Hobart, TAS, 7001 AUSTRALIA
E-mail: G.Peterson.aaa.pharm.utas.edu.au
Back to the Top